Effect of antilymphocyte serum on parameters of growth of MCA-induced tumours

Effects of a Single Dose of Rabbit Anti-mouse Lymphocyte Serum on Tumors Induced in Mice by 7,12-Dimethylbenz (a) anthracene Given at Birth

The effects of ALS (anti-lymphocyte serum) and NRS (normal rabbit serum) treatments on the development of malignant lymphoma, lung, subcutaneous and skin tumors induced in mice by 7,12-dimethylbenz (a) anthracene (DMBA) are described. Groups of Charles-River mice, injected at birth with a dose of 100 μg of DMBA, received a single injection of ALS or NRS at the same time as DMBA administration or 10, 20, 30, 40 and 50 days after birth. Incidence, latency, histology and spread of the tumors were studied in all groups. It was found that both ALS and NRS increased tumor incidence and shortened their latency period. Malignant lymphomas were the main tumors whose latency was shortened either by ALS or NRS treatment. In addition ALS treatment apparently increased dissemination of DMBA induced lymphoma in bone marrow.

Effects of Repeated Injections of Rabbit Anti-mouse Lymphocyte Serum on Tumors Induced in Mice by 7,12-dimethylbenz (a) anthracene Given at Birth

The present paper describes the effects of repeated administration of rabbit anti-mouse lymphocyte serum (ALS) or normal rabbit serum (NRS) on tumors induced in Charles–River mice by 7,12-dimethylbenz (a) anthracene (DMBA) given at birth. ALS or NRS were given at the same time of DMBA administration and subsequently at weekly intervals for the first 10 weeks of life or at daily intervals for 7 days during the first, second, third or fourth week of life. Incidence, latency, diffusion and histology of the tumors were studied. It was found that either chronic administration of ALS or treatment of very young mice with the serum, greatly reduced the mean survival time of mice, markedly increased the number of tumor bearing mice and the incidence of all histological types of tumors, and decreased their latency period. Administration of ALS in the other experimental groups gave results essentially similar to those observed in DMBA control and NRS treated mice.

The perturbed cell proliferation kinetics of the EMT6/M/AC tumour in mice treated with anti-mouse lymphocyte serum

The cell proliferation kinetics of the EMT6/M/AC tumour were determined at two volumes, 6-3 mm3 and 180 mm3, in mice treated with anti-mouse lymphocyte serum, AMLS. Comparison of the growth curve with that obtained in non-AMLS treated animals showed a marked increase in the growth rate at all volumes in the treated group. In contrast, the cell cycle time and the intermitotic phase times were not significantly different in the treated and untreated groups at comparable volumes. The increase in the growth rate in AMLS treated mice was obtained in spite of decreases in both the rate constant for cell production and the growth fraction, and was due to a marked decrease in the rate constant for cell loss.

Successful renal transplantation in patients with prior history of malignancy

Eleven selected patients with a history of cancer have received renal transplants. In three patients the malignancies were diagnosed and treated before renal failure developed. Two patients underwent bilateral nephrectomies for the treatment of bilateral renal malignancy. In six patients the malignancy developed while they were uremic, and they received transplants after treatment of the tumor. Recurrent tumor developed in only one of the 11 (9 per cent) patients after receiving the transplant. Thus, patients with a history of malignancy can receive a transplant without accelerating growth of the tumor. We recommend a minimum period of one year between tumor treatment and transplantation to observe for tumor recurrences or metastases. A longer period of observation may be necessary in patients who have tumors with a poorer prognosis.

The role of the spleen and immunity in the metastatic pattern of a murine reticulum cell sarcoma

A reticulum cell sarcoma (RCS) which initially metastasizes selectively to the spleen in C3H/HeN mice has been studied. Previous reports indicated that removal of the spleen results in widespread metastases of this tumor. The current experiments utilized a parabiotic system to determine the effect of additional splenic tissue on the gross and microscopic metastatic pattern of this RCS. The results were that the addition of a second spleen in the parabiotic group was followed by a significant decrease in visceral metastases compared with the splenectomized group. Parabiotic animals with splenectomized partners and sham-operated animals did not significantly differ from control (single) animals, with all three of these groups showing visceral metastatic spread intermediate between the parabiotic and splenectomized groups. The protective effect of additional spleen against visceral metastases was found not to be immunologic, since immunosuppression of mice by irradiation produced a metastatic pattern similar to that of control animals.

Heterologous antilymphocyte serum hastens the growth of 7,12-dimethylbenz(alpha)anthracene induced tumours in mice

The present paper describes the effects of repeated administration of rabbit anti-mouse lymphocyte serum (ALS) or normal rabbit serum (NRS) on tumours induced in Charles-River mice by 7,12-dimethylbenz(α)anthracene (DMBA) given at birth. ALS or NRS were given either at the time of DMBA administration and subsequently at weekly intervals for the first 10 weeks of life, or at daily intervals for 7 days during the first, second, third or fourth week of life. The incidence and histology of the tumours were studied. It was found that treatment of very young mice with ALS greatly reduced the mean survival time of mice and significantly increased the incidence of malignant lymphoma. The incidence of lung tumours was found to be significantly increased in the animals injected with ALS during the second week of life.Treatment with ALS in the other experimental groups gave results essentially similar to those observed in DMBA control and NRS treated mice.

Do metastases metastasize?

Images